The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of BioAtla Inc (NASDAQ: BCAB) closed at $3.13 in the last session, up 1.29% from day before closing price of $3.09. In other words, the price has increased by $1.29 from its previous closing price. On the day, 0.56 million shares were traded. BCAB stock price reached its highest trading level at $3.41 during the session, while it also had its lowest trading level at $3.01.
Ratios:
We take a closer look at BCAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on September 15, 2022, initiated with a Mkt Outperform rating and assigned the stock a target price of $17.
On May 05, 2022, Credit Suisse Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $35 to $5.
On March 21, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on March 21, 2022, with a $25 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 26 ’23 when MCBRINN SYLVIA bought 4,000 shares for $2.33 per share. The transaction valued at 9,320 led to the insider holds 15,125 shares of the business.
SHORT JAY M PHD bought 50,000 shares of BCAB for $106,910 on Dec 20 ’23. The Chief Executive Officer now owns 1,439,283 shares after completing the transaction at $2.14 per share. On Dec 19 ’23, another insider, STEINMAN LAWRENCE, who serves as the Director of the company, bought 20,000 shares for $2.05 each. As a result, the insider paid 41,048 and bolstered with 38,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAB now has a Market Capitalization of 150572720 and an Enterprise Value of 39607856.
Stock Price History:
The Beta on a monthly basis for BCAB is 1.29, which has changed by -0.06646526 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, BCAB has reached a high of $4.07, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is 9.78%, while the 200-Day Moving Average is calculated to be 35.75%.
Shares Statistics:
According to the various share statistics, BCAB traded on average about 605.31K shares per day over the past 3-months and 911490 shares per day over the past 10 days. A total of 48.08M shares are outstanding, with a floating share count of 38.78M. Insiders hold about 19.39% of the company’s shares, while institutions hold 54.48% stake in the company. Shares short for BCAB as of 1713139200 were 5415358 with a Short Ratio of 8.95, compared to 1710460800 on 5127011. Therefore, it implies a Short% of Shares Outstanding of 5415358 and a Short% of Float of 12.590000000000002.
Earnings Estimates
The current market rating for BioAtla Inc (BCAB) reflects the collective analysis of 4.0 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.79 for the current quarter, with a high estimate of -$0.71 and a low estimate of -$1.0, while EPS last year was -$0.63. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.44 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$2.74 and -$2.78 for the fiscal current year, implying an average EPS of -$2.76. EPS for the following year is -$1.93, with 5.0 analysts recommending between -$1.78 and -$2.14.
